Avance advises Mehiläinen in the acquisition of Docrates, a comprehensive cancer diagnostics and treatment provider serving patients from up to 50 different countries each year. As a private cancer hospital, Docrates is a pioneer in Europe and the only one of its kind in the Nordic countries.
The consummation of the transaction is subject to approval by the Finnish Competition and Consumer Authority.